AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01311102
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.33 cc 2% liquid lidocaine
Trial: NCT00006127
Drug: amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02342067
Drug: Cenicriviroc
RxNorm normalized name: Cenicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
Trial: NCT02342067
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
Trial: NCT02276300
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sargramostim is part of Her2 vaccination
Trial: NCT02276300
Drug: HER2-Peptid-Vakzine
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
Trial: NCT02276300
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod is part of Her2 vaccination
Trial: NCT04377646
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
Trial: NCT04377646
Drug: Hydroxychloroquine (placebo)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
Trial: NCT01011010
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.
Trial: NCT01011010
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
Trial: NCT00522249
Drug: Pegylated Alfa Interferon
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
Trial: NCT00522249
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
Trial: NCT00522249
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
Trial: NCT02182193
Drug: BIBF 1120 capsules charge 1
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182193
Drug: BIBF 1120 capsules charge 2
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01660906
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablets, oral, 100 mg, Once daily, Up to12 months on study,
Trial: NCT02142049
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib
Trial: NCT02142049
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide
Trial: NCT03248973
Drug: Ampicillin Injection
RxNorm normalized name: ampicillin Injection
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin injection 2 g q4h for 3 weeks
Trial: NCT00864448
Drug: Ramipril10 mg Capsules, single dose
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Trial: NCT00454558
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
Trial: NCT02283060
Drug: Stribild
RxNorm normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be administered orally, once daily with food.
Trial: NCT02283060
Drug: Atripla
RxNorm normalized name: Atripla
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be administered orally, once daily at bedtime on an empty stomach
Trial: NCT00058838
Drug: sumanirole
RxNorm normalized name: Sumanirole
DrugBank: Sumanirole (DB06477)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04654416
Drug: Corticosteroid with or without colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We describe the clinical outcome of patients treated with corticosteroid and colchicine
Trial: NCT02570490
Drug: sodium fusidate
RxNorm normalized name: Sodium fusidate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02570490
Drug: linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04622579
Drug: lenalidomide combined with rituximab
RxNorm normalized name: Lenalidomide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
Trial: NCT00078559
Drug: Valgancyclovir
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
Trial: NCT00078559
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
Trial: NCT00078559
Drug: Pentamidine
RxNorm normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
Trial: NCT00078559
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
Trial: NCT00078559
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
Trial: NCT00424528
Drug: Arformoterol Tartrate Inhalation Solution
RxNorm normalized name: ARFORMOTEROL TARTRATE 15 ug in 2 mL RESPIRATORY (INHALATION) SOLUTION [Arformoterol Tartrate Inhalation Solution]
DrugBank: Arformoterol (DB01274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
Trial: NCT00424528
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
Trial: NCT00424528
Drug: Arformoterol and Tiotropium
RxNorm normalized name: formoterol and tiotropium bromide
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
Trial: NCT01159626
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 20 mg dose as two 10mg controlled release tablets
Trial: NCT01159626
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 40 mg dose as four 10mg controlled release tablets
Trial: NCT01159626
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single 60 mg dose as six 10mg controlled release tablets
Trial: NCT01159626
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
Trial: NCT00274053
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518921
Drug: Capadenoson (BAY 68-4986)
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg Capadenoson, double dummy
Trial: NCT00518921
Drug: Capadenoson (BAY 68-4986)
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg Capadenoson, double dummy
Trial: NCT00518921
Drug: Capadenoson (BAY 68-4986)
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg Capadenoson, double dummy
Trial: NCT01757756
Drug: Pf-05175157
RxNorm normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg administered twice daily for 14 days
Trial: NCT01757756
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam 3-mg admistered as single doses on Day 0 and Day 11.
Trial: NCT03704376
Drug: 30 ml of 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03704376
Drug: 15 ml of 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03704376
Drug: 100 mcg clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03114254
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.
Trial: NCT00675740
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets 4 mg daily
Trial: NCT02053350
Drug: Alanyl-glutamine
RxNorm normalized name: ALANYL-GLUTAMINE
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl-glutamine, 44g, taken by mouth daily for 10 days
Trial: NCT01741623
Drug: Bisoprolol Fumarate Tablet 10 mg
RxNorm normalized name: Bisoprolol Fumarate
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet once a day
Trial: NCT01741623
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet once a day
Trial: NCT00001533
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01560390
Drug: Rémifentamil + KETAMINE
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
Trial: NCT01560390
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
Trial: NCT00629187
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
Trial: NCT00933569
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment period: 21 consecutive days
Trial: NCT03466333
Drug: Enalapril Maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
Trial: NCT01512225
Drug: Domperidone maleate
RxNorm normalized name: domperidone maleate
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: domperidone maleate tablet 10 mg orally three times daily for 28 days
Trial: NCT01512225
Drug: Domperidone maleate
RxNorm normalized name: domperidone maleate
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: domperidone maleate tablet 10 mg orally three times daily for 14 days
Trial: NCT01412944
Drug: secukinumab 150mg
RxNorm normalized name: SECUKINUMAB 150MG/ML INJ,SYR,1ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: secukinumab 150mg (2 injections per dose)
Trial: NCT01412944
Drug: secukinumab 10mg/kg i.v. regimen
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: secukinumab 10mg/kg i.v. regimen
Trial: NCT00360308
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01126593
Drug: 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
Trial: NCT00093301
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00093301
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03830034
Drug: Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed.
Trial: NCT04471818
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
Trial: NCT01483001
Drug: Cancer Stem Cells Sensitivity Assay
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
Trial: NCT01227681
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
Trial: NCT01091324
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg, bid
Trial: NCT01091324
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03455426
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
Trial: NCT00321919
Drug: epoetin beta [NeoRecormon]
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
Trial: NCT00321919
Drug: epoetin beta [NeoRecormon]
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
Trial: NCT03398005
Drug: CaPre
RxNorm normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 x 1 g capsules administered orally once a day for 26 weeks
Trial: NCT01217073
Drug: Omarigliptin
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
Trial: NCT01217073
Drug: Placebo to omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
Trial: NCT01217073
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg oral tablet or capsule administered once daily
Trial: NCT01217073
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg oral tablet administered once or twice daily
Trial: NCT01217073
Drug: Placebo to metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching placebo to metformin oral tablet administered once daily
Trial: NCT02943603
Drug: mFLOFOX6 + pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
Trial: NCT03989466
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01569516
Drug: Octohydroaminoacridine Succinate Tablets
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg, tid
Trial: NCT01569516
Drug: Octohydroaminoacridine Succinate Tablets
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
Trial: NCT01569516
Drug: Octohydroaminoacridine succinate Tablets
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
Trial: NCT00706121
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 IU daily by mouth for 7 - 12 years
Trial: NCT00706121
Drug: Selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg daily for 7 - 12 years
Trial: NCT00706121
Drug: Vitamin E placebo
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 pill by mouth daily for 7 - 12 years